Drug and Therapeutics Bulletin 2005;43:1-6; doi:10.1136/dtb.2005.4311
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Taking stock of coxibs

Relevant BNF section: 10.1.1

Highly selective COX-2 inhibitors ('coxibs') were developed in an attempt to minimise severe gastrointestinal toxicity associated with conventional NSAIDs, without loss of anti-inflammatory efficacy. Five years ago, we concluded that the evidence then available indicated, at most, a small advantage for rofecoxib and celecoxib (the first coxibs to be marketed) over conventional NSAIDs in terms of reduced risk of severe gastrointestinal complications, such as bleeding or perforation of gastric or duodenal ulcers.¹ In September 2004, newly released evidence about cardiovascular risk with rofecoxib led Merck Sharp & Dohme to voluntarily withdraw the drug worldwide.² This has raised questions about the balance of benefit and risk with coxibs in general. Here we discuss the evidence relating to the gastrointestinal and cardiovascular safety of coxibs in patients with osteoarthritis (OA) or rheumatoid arthritis (RA).

This article has been cited by other articles:

				C. Paton and I N. Ferrier SSRIs and gastrointestinal bleeding BMJ, September 10, 2005; 331(7516): 529 - 530. [Full Text] [PDF]

				A. Albini and D. M. Noonan Rescuing COX-2 Inhibitors From the Waste Bin J Natl Cancer Inst, June 1, 2005; 97(11): 859 - 860. [Full Text] [PDF]